Radiopharm Theranostics selected to present positive RAD101 interim data
RAD101 PET in a U.S. Phase 2b imaging trial showed 93% concordance with MRI across evaluable lesions, and the company says it met the primary endpoint.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.